The Biology of Natural Killer Cells and Implications for Therapy of Human Disease
- 1 August 2001
- journal article
- review article
- Published by Mary Ann Liebert Inc in Journal of Hematotherapy & Stem Cell Research
- Vol. 10 (4) , 451-463
- https://doi.org/10.1089/15258160152509073
Abstract
Natural killer (NK) cells are unique lymphocytes capable of lysing target cells without prior immunization. NK cells activated with cytokines, like interleukin-2 (IL-2), have been used since the 1980s as adoptive immunotherapy against metastatic solid tumors, but their effectiveness has been limited. The mechanisms by which NK cells recognize their targets are complex, including newly identified receptors that recognize class I MHC molecules. Understanding these mechanisms may support the use of NK cells as clinical therapy against infectious diseases and cancer. We have been interested in the use of NK cells clinically for their potential to eradicate minimal residual disease and prevent relapses after autologous stem cell transplantation. Several strategies are discussed to increase the specificity and efficacy of NK cell therapy. One method is to increase the targeting of NK cells by the use of monoclonal antibodies. Another approach uses allogeneic NK cells to overcome the inhibitory receptor mechanisms that may block target cell lysis by recognition of class I molecules. These and other novel strategies may prove to be attractive and effective immunotherapeutic tools to manipulate NK cells to fight human disease.Keywords
This publication has 125 references indexed in Scilit:
- In search of the ‘missing self’: MHC molecules and NK cell recognitionPublished by Elsevier ,2003
- Effect of intraportal adoptive immunotherapy on liver metastases after resection of pancreatic cancerBritish Journal of Surgery, 2000
- Immunotherapy of Malignant Melanoma in a SCID Mouse Model Using the Highly Cytotoxic Natural Killer Cell Line NK-92Journal of Hematotherapy, 1999
- Early Murine Cytomegalovirus (MCMV) Infection Induces Liver Natural Killer (NK) Cell Inflammation and Protection Through Macrophage Inflammatory Protein 1α (MIP-1α)–dependent PathwaysThe Journal of Experimental Medicine, 1998
- A Phase III randomized study of interleukin‐2 lymphokine‐activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinomaCancer, 1997
- Apoptosis by Death FactorCell, 1997
- Interleukin-8 Production by CD16−CD56bright Natural Killer Cells in the Human Early Pregnancy DeciduaBiochemical and Biophysical Research Communications, 1994
- Increased release of interleukin‐1 and tumour necrosis factor by interleukin‐2‐induced lymphokine‐activated killer cells in the presence of cisplatin and FK‐565Immunology & Cell Biology, 1992
- Severe Herpesvirus Infections in an Adolescent without Natural Killer CellsNew England Journal of Medicine, 1989
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985